FI906307A0 - Förfarande för framställning av terapeutiskt aktiva pyrimidinderivat - Google Patents

Förfarande för framställning av terapeutiskt aktiva pyrimidinderivat

Info

Publication number
FI906307A0
FI906307A0 FI906307A FI906307A FI906307A0 FI 906307 A0 FI906307 A0 FI 906307A0 FI 906307 A FI906307 A FI 906307A FI 906307 A FI906307 A FI 906307A FI 906307 A0 FI906307 A0 FI 906307A0
Authority
FI
Finland
Prior art keywords
alkyl
cycloalkyl
alkenyl
carbon atoms
group
Prior art date
Application number
FI906307A
Other languages
English (en)
Finnish (fi)
Other versions
FI95377C (sv
FI95377B (sv
Inventor
Rodney Brian Hargreaves
Paul William Marshall
Bernard Joseph Mcloughlin
Stuart Dennett Mills
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898909054A external-priority patent/GB8909054D0/en
Priority claimed from GB898910548A external-priority patent/GB8910548D0/en
Application filed by Ici Plc filed Critical Ici Plc
Publication of FI906307A0 publication Critical patent/FI906307A0/sv
Application granted granted Critical
Publication of FI95377B publication Critical patent/FI95377B/sv
Publication of FI95377C publication Critical patent/FI95377C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI906307A 1989-04-21 1990-12-20 Förfarande för framställning av terapeutiskt aktiva pyrimidinderivat FI95377C (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB8909054 1989-04-21
GB898909054A GB8909054D0 (en) 1989-04-21 1989-04-21 Amino heterocycles
GB8910548 1989-05-08
GB898910548A GB8910548D0 (en) 1989-05-08 1989-05-08 Heterocyclic compounds
PCT/GB1990/000595 WO1990012790A1 (en) 1989-04-21 1990-04-19 Pyrimidine derivatives
GB9000595 1990-04-19

Publications (3)

Publication Number Publication Date
FI906307A0 true FI906307A0 (sv) 1990-12-20
FI95377B FI95377B (sv) 1995-10-13
FI95377C FI95377C (sv) 1996-01-25

Family

ID=26295250

Family Applications (1)

Application Number Title Priority Date Filing Date
FI906307A FI95377C (sv) 1989-04-21 1990-12-20 Förfarande för framställning av terapeutiskt aktiva pyrimidinderivat

Country Status (28)

Country Link
US (1) US5223505A (sv)
EP (1) EP0422178B1 (sv)
JP (1) JP2528218B2 (sv)
KR (1) KR920700203A (sv)
CN (1) CN1024793C (sv)
AT (1) ATE112561T1 (sv)
AU (1) AU635260B2 (sv)
CA (1) CA2014457C (sv)
DE (1) DE69013112T2 (sv)
DK (1) DK0422178T3 (sv)
ES (1) ES2064727T3 (sv)
FI (1) FI95377C (sv)
GB (1) GB2230527B (sv)
GR (1) GR1000371B (sv)
HR (1) HRP930793A2 (sv)
HU (1) HU209586B (sv)
IE (1) IE63502B1 (sv)
IL (1) IL94062A (sv)
MW (1) MW9090A1 (sv)
MY (1) MY105637A (sv)
NO (1) NO177054C (sv)
NZ (1) NZ233292A (sv)
PL (2) PL165502B1 (sv)
PT (1) PT93823B (sv)
RU (1) RU2108329C1 (sv)
SI (1) SI9010799A (sv)
WO (1) WO1990012790A1 (sv)
YU (1) YU79990A (sv)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
GB9022644D0 (en) * 1990-10-18 1990-11-28 Ici Plc Heterocyclic compounds
US5952331A (en) * 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
US5958934A (en) * 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
KR20010041015A (ko) 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
KR100643419B1 (ko) 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체
DE19851421A1 (de) * 1998-11-07 2000-05-11 Boehringer Ingelheim Pharma Neue Pyrimidine, deren Herstellung und Verwendung
NZ517025A (en) 1999-09-24 2003-07-25 Janssen Pharmaceutica Nv Antiviral compositions
US6410726B1 (en) * 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
SK13752003A3 (en) * 2001-05-14 2004-11-03 Bristol Myers Squibb Pharma Co Substituted pyrazinones, pyridines and pyrimidines as ligands of factor releasing corticotropine
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
CN1867560A (zh) 2003-08-13 2006-11-22 武田药品工株式会社 4－嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06010571A (es) 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
EP1888537B1 (en) 2005-05-26 2013-09-11 Janssen R&D Ireland Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino benzonitrile
JP5027137B2 (ja) 2005-09-14 2012-09-19 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤の投与
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
WO2007089774A2 (en) * 2006-01-31 2007-08-09 Yale University Compositions and methods for treating cognitive disorders
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20080217501A1 (en) * 2007-02-14 2008-09-11 Chad Jensen Power a-frame
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
TWI401023B (zh) * 2008-02-06 2013-07-11 Du Pont 中離子農藥
US9616064B2 (en) 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use
WO2018187652A1 (en) 2017-04-06 2018-10-11 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine h4 modulators
AU2018352695A1 (en) 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB815833A (en) * 1956-09-26 1959-07-01 Boots Pure Drug Co Ltd Phenanthridine compounds
BE492034A (sv) * 1948-11-05
US2784124A (en) * 1953-07-01 1957-03-05 Howard R Moore Method of coating ferrous metal surface and composition therefor
US2748124A (en) * 1954-05-06 1956-05-29 Searle & Co 1-(4-anilino-2-pyrimidino)-3-alkylureas
US2845425A (en) * 1956-10-04 1958-07-29 Lilly Co Eli Substituted aminopyrimidines
DE1241832B (de) * 1963-02-23 1967-06-08 Hoechst Ag Verfahren zur Herstellung von Pyrimidiniumverbindungen
DE1445740A1 (de) * 1963-09-04 1968-11-28 Bayer Ag Verfahren zur Herstellung von Bispyrimidinium-Verbindungen
GB1229413A (sv) * 1967-06-14 1971-04-21
IN142539B (sv) * 1974-05-10 1977-07-23 Ciba Geigy India Ltd
US4339453A (en) * 1979-07-23 1982-07-13 Merck & Co., Inc. Antimicrobial aminopyrimidinium salts
EP0139613A1 (de) * 1983-08-29 1985-05-02 Ciba-Geigy Ag N-(2-Nitrophenyl)-4-aminopyrimidin-Derivate, deren Herstellung und Verwendung
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
DE3717480A1 (de) * 1987-05-23 1988-12-01 Shell Agrar Gmbh & Co Kg Neue herbizid und mikrobizid wirksame 2,6-diaminopyrimidine
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
HU903555D0 (en) 1991-05-28
NZ233292A (en) 1992-05-26
KR920700203A (ko) 1992-02-19
HRP930793A2 (en) 1996-08-31
MW9090A1 (en) 1991-11-13
YU79990A (en) 1991-10-31
DK0422178T3 (da) 1994-12-19
NO177054B (no) 1995-04-03
CA2014457A1 (en) 1990-10-21
NO905519L (no) 1991-02-20
CN1047080A (zh) 1990-11-21
SI9010799A (en) 1995-08-31
RU2108329C1 (ru) 1998-04-10
PL165502B1 (pl) 1994-12-30
GR1000371B (el) 1992-06-30
GR900100304A (en) 1991-09-27
HU209586B (en) 1994-08-29
FI95377C (sv) 1996-01-25
HUT56080A (en) 1991-07-29
ATE112561T1 (de) 1994-10-15
MY105637A (en) 1994-11-30
IE901258L (en) 1990-10-21
AU635260B2 (en) 1993-03-18
JP2528218B2 (ja) 1996-08-28
GB9007964D0 (en) 1990-06-06
EP0422178B1 (en) 1994-10-05
PT93823B (pt) 1996-09-30
NO177054C (no) 1995-07-12
FI95377B (sv) 1995-10-13
IE63502B1 (en) 1995-05-03
CA2014457C (en) 1999-09-28
CN1024793C (zh) 1994-06-01
PT93823A (pt) 1990-11-20
DE69013112D1 (de) 1994-11-10
US5223505A (en) 1993-06-29
ES2064727T3 (es) 1995-02-01
IL94062A (en) 1995-11-27
DE69013112T2 (de) 1995-01-26
PL165917B1 (pl) 1995-03-31
AU5435490A (en) 1990-11-16
IL94062A0 (en) 1991-01-31
EP0422178A1 (en) 1991-04-17
WO1990012790A1 (en) 1990-11-01
GB2230527A (en) 1990-10-24
NO905519D0 (no) 1990-12-20
JPH03505741A (ja) 1991-12-12
GB2230527B (en) 1993-05-05

Similar Documents

Publication Publication Date Title
FI906307A0 (sv) Förfarande för framställning av terapeutiskt aktiva pyrimidinderivat
ES2055535T3 (es) Derivados de amina.
MY106091A (en) Heterocyclic compounds.
ATE48994T1 (de) Benzimidazol-derivat, verfahren zu seiner herstellung und pharmazeutische zusammensetzung.
AU639154B2 (en) New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
JO1631B1 (en) Derivatives of permidine
ATE131480T1 (de) Pyrimidoindolderivate und verfahren zu ihrer herstellung
FR2655042B1 (fr) Nouvelles benzothiazolinones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ZENECA LIMITED

BB Publication of examined application
MM Patent lapsed

Owner name: ZENECA LIMITED